Intensive Studies for Recertification: Pharmacotherapy (Cert # L209094)

ACPE Numbers:

0204-0000-19-233-H01-P
0204-0000-19-269-H04-P
0204-0000-19-289-H01-P
0204-0000-19-306-H01-P

Content Release Date: 02/05/2020
Expiration Date: 02/02/2021
Activity Type: Application-based
CE Credits: 6.0 hours

Accreditation for Pharmacists

 The American Society of Health-System Pharmacists and the American Pharmacists Association (APhA) are accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 

These activities were recorded during a live educational event on December 9-11, 2019 at the Midyear Clinical Meeting in Las Vegas, Nevada. Learners who claimed credit for the live activities should not claim credit for these home study activities.

Target Audience

These recertification activities are intended for board certified pharmacists seeking to update their knowledge and skills in:

  • Cardiology
  • Critical Care
  • Clinical Topics/Therapeutics
  • Infectious Diseases
  • IV Therapy/Infusion Devices
  • Pediatric Pharmacotherapy
  • Safety/Quality

Activity Overview

The Intensive Study Package is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). Using a case-based approach, the activities provide high-level, interactive discussions on contemporary and emerging issues in pharmacotherapy.

The Pharmacotherapy Intensive Study Recertification Package consists of 4 activities (see table below) recorded during a live educational event on December 9-11, 2019 at the Midyear Clinical Meeting in Las Vegas, Nevada, and provides up to 6.0 hours of continuing pharmacy education and/or recertification credit.  

These activities are part of the ASHP professional development program for BCPS recertification approved by the BPS.  For pharmacists who maintain more than one certification, three of the activities are approved for multiple specialties (see table below).

Recertification Credit*

Board certified pharmacists are eligible to receive up to 6.0 hours of recertification credit for completing this package. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

Learning Module

ACPE Number

Credit Hours

Specialty

*Assessment Pass Point

The Use of Ketamine in Critically Ill Adults and Children

0204-0000-19-233-H01-P

1.5

BCPS, BCCCP, BCPPS

73%

Strategies to Maximize the Safety of your Smart Pumps

0204-0000-19-269-H04-P

1.5

BCPS, BCCCP

78%

Combating the #1 Killer in America: New Evidence and Guidelines for Primary Prevention of Cardiovascular Disease

0204-0000-19-289-H01-P

1.5

BCPS

73%

Controversies in Treating Infective Endocarditis in People Who Inject Drugs

0204-0000-19-306-H01-P

1.5

BCPS, BCCCP

66%

 

Learning Objectives

The Use of Ketamine in Critically Ill Adults and Children
0204-0000-19-233-H01-P

At the conclusion of this application-based educational activity, participants should be able to do the following:

  • Apply recent literature and logistical considerations in the use of ketamine in cases involving critically ill adult and pediatric patients.
  • Develop strategies for the effective use of ketamine for pain management and attenuation or reversal of opioid tolerance in patients in the emergency department or intensive care unit.
  • Explain the role of ketamine in adult and pediatric patients with status epilepticus.
  • Compare and contrast the use of ketamine for pain management, attenuation of opioid tolerance, and treatment of status epilepticus, between adult and pediatric patients.

This activity is approved for Board Certified Critical Care Pharmacist (BCCCP), Board Certified Pediatric Pharmacy Specialist (BCPPS), and Board Certified Pharmacotherapy Specialist (BCPS) recertification credit.

Strategies to Maximize the Safety of your Smart Pumps
0204-0000-19-269-H04-P

At the conclusion of this application-based educational activity, participants should be able to do the following:

  • Analyze strategies to maximize smart pump safety.
  • Devise methods for evaluating smart pump data.
  • Develop an action plan for establishing interoperability between smart pumps and the electronic medical record (EMR).

This activity is approved for Board Certified Critical Care Pharmacist (BCCCP) and Board Certified Pharmacotherapy Specialist (BCPS) recertification credit.

Combating the #1 Killer in America: New Evidence and Guidelines for Primary Prevention of Cardiovascular Disease
0204-0000-19-289-H01-P

At the conclusion of this application-based educational activity, participants should be able to do the following:

  • Apply the American College of Cardiology/American Heart Association (ACC/AHA) hypertension and cholesterol guidelines in making treatment recommendations for primary prevention of cardiovascular events.
  • Evaluate evidence-based guideline recommendations for the treatment of patients with hypertension, including treatment-resistant hypertension.
  • Interpret evidence-based guideline recommendations for the use of statin therapy for primary prevention of cardiovascular events.
  • Interpret clinical trials evaluating aspirin in primary prevention and clinical practice guideline recommendations.
  • Given a patient without cardiovascular disease, develop a medication regimen for the prevention of cardiovascular events that reflects current clinical guidelines and available evidence.

This activity is approved for Board Certified Pharmacotherapy Specialist (BCPS) recertification credit.

Controversies in Treating Infective Endocarditis in People Who Inject Drugs
0204-0000-19-306-H01-P

At the conclusion of this application-based educational activity, participants should be able to do the following:

  • Describe the characteristics of infective endocarditis (IE) in people who inject drugs (PWID).
  • Evaluate clinical controversies in the management of IE in PWID, ranging from acute management to the use of outpatient parenteral antimicrobial therapy.
  • Given a patient case, develop and evidence-based IE regimen that facilitates switching from parenteral to oral antimicrobial therapy.

This activity is approved for Board Certified Critical Care Pharmacist (BCCCP) and Board Certified Pharmacotherapy Specialist (BCPS) recertification credit.

Planners, Presenters, and Reviewers 

Full Faculty Bios

Katie Barber, Pharm.D.
Assistant Professor
University of Mississippi
Jackson, Mississippi 
James Gilmore, Pharm.D., BCCCP, BCPS
Pharmacy Manager, Critical Care & Emergency Department
Cedars-Sinai
Los Angeles, California
Kaitlin M. Hughes, Pharm.D., BCPPS
Clinical Pharmacist Pediatric Intensive Care
Riley Hospital for Children at IU Health
Indianapolis, Indiana
Rachel Kenney, Pharm.D., BCIDP
Pharmacy Specialist, Antimicrobial Stewardship Residency Program Director, PGY2 Infectious Diseases
Henry Ford Hospital
Department of Pharmacy Services
Detroit, Michigan
Joel C. Marrs, Pharm.D., M.P.H., BCACP, BCCP, BCPS, CLS, FAHA, FASHP, FCCP, FNLA
Associate Professor
University of Colorado Skaggs School of Pharmacy and Pharmaceutical Science
Aurora, Colorado
Jennifer Robertson, Pharm.D., BCPS
Medication Outcomes & Safety Officer
St. Jude Children’s Research Hospital
Pharmaceutical Department
Memphis, Tennessee
Joseph J. Saseen, Pharm.D., BCACP, BCPS, CLS
Professor and Vice Chair
University of Colorado Anschutz Medical Campus
Aurora, Colorado
Cortney Swiggart, Pharm.D.
System Medication Safety Officer
Methodist Le Bonheur Healthcare
Memphis, Tennessee
Christopher Betz, Pharm.D., BCPS, FASHP, FKSHP
Professor, Department of Clinical and Administrative Sciences
Sullivan University College of Pharmacy
Cardiology Clinical Pharmacy Specialist
Jewish Hospital Rudd Heart and Lung Center
Louisville, Kentucky
Angela L. Bingham, Pharm.D., BCCCP, BCNSP, BCPS
Assistant Professor of Clinical Pharmacy
Philadelphia College of Pharmacy at University of the Sciences
Philadelphia, Pennsylvania
Clinical Pharmacy Specialist
Cooper University Hospital
Camden, New Jersey
Mary M. Hess, Pharm.D., B.S.Pharm., BCCCP, FASHP, FCCM, FCCP
Associate Dean
Jefferson College of Pharmacy
Philadelphia, Pennsylvania
Peter N. Johnson, Pharm.D., BCPPS, BCPS, FCCM, FPPAG
Associate Professor of Pharmacy Practice
University of Oklahoma College of Pharmacy
Adjunct Associate
University of Oklahoma College of Medicine
Oklahoma City, Oklahoma
Douglas Slain, Pharm.D., B.S.Pharm., BCPS, FASHP
Professor and Infectious Diseases Clinical Specialist
West Virginia University (WVU) and WVU Hospitals and Clinics
Canonsburg, Pennsylvania
Paul M. Szumita, Pharm.D., BCCCP, BCPS, FASHP, FCCM
Clinical Pharmacy Practice Manager
Brigham and Women's Hospital
Foxboro, Massachusetts

Holly L. Byrnes, Pharm D., BCPS
Susan R. Dombrowski, M.S., R.Ph.
Kristi Hofer, Pharm.D.
Robert Tremmel, Pharm.D.

Shannon Allcron, Pharm.D., BCCCP, BCPS
Megan Anderson, Pharm.D., BCPS
Daniel Baker, Pharm.D., BCPS, BCCCP, BCIDP
Kimberly Blanton, Pharm.D., BCPS
Quintin Broussard, Pharm.D., BCPS, BCCCP, BCNSP
Jeffrey Bruno, Pharm.D., BCPS, BCNSP, BCCCP, FCCM
Laura Celmins, Pharm.D., BCPS, BCCCP
Darlene Chaykosky , Pharm.D., BCPS, BCCCP
Nathan Cookson, Pharm.D., BCPS
Robin Coulter, Pharm.D., MBA, BCPS
Lauren Dickerson, Pharm.D., BCPS, BCCCP, BCIDP
Tuong Diep, Pharm. D, BCPS, BCCCP, BCIDP
Alyssa Douville, Pharm.D., BCPS, BCCCP
Roxana Dumitru, Pharm.D., BCPS, BCCCP
Lien Duong, Pharm.D, BCPS, BCCCP
Tatyana Duverglas, Pharm.D., BCPS, BCCCP
Karly Erickson, Pharm.D., BCPS, BCCCP
Mercedes Fraga, Pharm.D., BCPS, BCCCP, BCIDP
Jennifer Gass, Pharm.D., BCPS, BCCCP
Julie Haase, Pharm.D., BCPS, BCCCP
Sarah Hale, Pharm.D., BCPPS
Nicole Harger, Pharm.D., BCPS, BCCCP
Jamie Hoffman, Pharm.D., BCPS
Julie Kalabalik, Pharm.D., BCPS, BCCCP
Mohamed Kholy, B.Pharm., Pharm D, BCCCP, BCPS, MSC
Emily Kurzen, Pharm.D., BCPPS
Kimberley Limouze, Pharm.D., BCPS, BCCCP
Susan Norman, Pharm.D., BCPPS, BCPS
Marla O'Shea-Bulman, Pharm.D., BCPS
Chris Oswald, Pharm.D., BCPS, BCCCP
Tracy Peterson, Pharm.D., BCPS, BCCCP
Jill Schultz, Pharm.D., BCPS, BCCCP
Ashley Selby, Pharm.D., BCPS, BCCCP
Laura Siemianowski, Pharm.D., BCPS, BCCCP
Zachary Smith, Pharm.D., BCPS, BCCCP
Amy Snowden, Pharm.D., BCPPS
Shannon Song, Pharm.D., BCPPS
Janesha Thomas, Pharm.D., BCPPS
Julie Tremblay, BCPPS
Antonia Vilella, Pharm.D., BCCCP, BCPS
Victoria Wallace, Pharm.D., BCPS
Matthew Wanat, Pharm.D., BCPS, BCCCP, FCCM
Jessica Whalen, Pharm.D., BCCCP, BCPS
Sharon Wilson, Pharm.D., BCCCP, BCPS
Amy Wojciechowski, Pharm.D., BCPS, BCIDP, BCCCP, CIC
Mark Woods, B.S., Pharm.D., BCPS

 

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, ASHP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual of his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring the in the last 12 months with a commercial interest whose products or series may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content.

All faculty and planners for ASHP education activities are qualified and selected by ASHP and required to disclose any relevant financial relationships with commercial interests. ASHP identifies and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

Katie E. Barber: Advisory Board and Speakers Bureau, Paratek Pharmaceuticals (Self); and Advisory Board, Tetraphase Pharmaceuticals Inc. (Self).

Rachel Kenney: Employee, Stockholder/Ownership Interest (excluding diversified mutual funds), Medtronic Inc (Spouse/Partner).

All other planners, presenters, and reviewers of this session report no financial relationships relevant to this activity.

    Methods and CE Requirements

    Activities consist of audio/ video/PDF files, an attestation statement, and activity evaluation. Learners must review all content and complete the attestation statement and course evaluation to receive continuing pharmacy education credit for each activity. 

    Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

    System Technical Requirements

    Learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating web sites. 

    View the minimum technical and system requirements for learning activities. 

    Development

    These activities were developed by ASHP.